Transport Mechanisms of Squalenoyl-Adenosine Nanoparticles Across the Blood–Brain Barrier
Source abstract
Abstract
Drug delivery to the brain is one of the major challenges in the treatment of cerebral diseases and implies extensive understanding of nanomedicine transcytosis pathways across the blood–brain barrier (BBB). In this study, we investigated the interaction of squalenoyl-adenosine nanoassemblies (SQAd NAs) with human brain endothelial cells, concerning their endocytotic pathway using chemical inhibitors and nanostructure integrity using Förster resonance energy transfer (FRET). Practically, SQAd NAs were labeled with two different organic dyes as a donor–acceptor FRET pair to form FRET SQAd NAs with diameters of ca. 120 nm. Using the human cerebral endothelial cell line, hCMEC/D3, as a well-recognized BBB model, we demonstrated that the NAs were internalized mainly by LDL receptors-mediated endocytosis, then progressively disassembled inside the cells, and finally exocytosed as single molecules. These observations allow explaining the previously described pharmacological efficiency of the SQAd NAs in both a cerebral ischemia model and a spinal cord injury model, confirming that the endothelial cells of the neurovascular unit may represent a very promising therapeutic target for the treatment of certain neurological diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Transport and Resistance Mechanisms · Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
NanoBioPhotonics, Institut d’Electronique Fondamentale, Université Paris-Sud, 91405 Orsay Cedex, France
Funding
European Research Council · Seventh Framework Programme
References (55)
Show source-provided references
1. Alavijeh M. S. · NeuroRx · 2005 · 2 · 55410.1602/neurorx.2.4.554 ↗
2. Pangalos M. N. · Nat. Rev. Drug Discovery · 2007 · 6 · 52110.1038/nrd2094 ↗
3. Pardridge W. M. · J. Cereb. Blood Flow Metab. · 2012 · 32 · 195910.1038/jcbfm.2012.126 ↗
4. Pardridge W. M. · Pharm. Sci. Technol. Today · 1999 · 2 · 4910.1016/S1461-5347(98)00117-5 ↗
5. Gao H. · Pharm. Res. · 2013 · 30 · 248510.1007/s11095-013-1122-4 ↗
6. Kreuter J. · Adv. Drug. Delivery Rev. · 2014 · 71 · 210.1016/j.addr.2013.08.008 ↗
7. Walters R. · ASN Neuro. · 2012 · 4 · 38310.1042/AN20120042 ↗
8. Couvreur P. · Nano Lett. · 2006 · 6 · 254410.1021/nl061942q ↗
9. Gaudin A. · Nat. Nanotechnol. · 2014 · 9 · 105410.1038/nnano.2014.274 ↗
10. Weksler B. B. · FASEB J. · 2005 · 19 · 187210.1096/fj.04-3458fje ↗
11. Poller B. · J. Neurochem. · 2008 · 107 · 135810.1111/j.1471-4159.2008.05730.x ↗
12. Lindner C. · Exp. Transl. Stroke Med. · 2012 · 4 · 910.1186/2040-7378-4-9 ↗
13. Ohtsuki S. · Mol. Pharmaceutics · 2013 · 10 · 28910.1021/mp3004308 ↗
14. Salvati E. · Int. J. Nanomedicine · 2013 · 8 · 1749
15. Xie Y. · J. Controlled Release · 2005 · 105 · 10610.1016/j.jconrel.2005.03.005 ↗
16. Kratzer I. · J. Controlled Release · 2007 · 117 · 30110.1016/j.jconrel.2006.11.020 ↗
17. Ke W. · Biomaterials · 2009 · 30 · 697610.1016/j.biomaterials.2009.08.049 ↗
18. Liu Y. · Biomaterials · 2010 · 31 · 524610.1016/j.biomaterials.2010.03.011 ↗
19. Xin H. · Biomaterials · 2012 · 33 · 816710.1016/j.biomaterials.2012.07.046 ↗
20. Garcia-Garcia E. · Int. J. Pharm. · 2005 · 298 · 31010.1016/j.ijpharm.2005.03.030 ↗
21. Georgieva J. V. · Mol. Ther. · 2011 · 19 · 31810.1038/mt.2010.236 ↗
22. Wolak D. J. · Mol. Pharmaceutics · 2013 · 10 · 149210.1021/mp300495e ↗
23. Medintz I. H. · 2014
24. Li Y. · ACS Nano · 2012 · 6 · 948510.1021/nn302317j ↗
25. Chen H. · Langmuir · 2008 · 24 · 521310.1021/la703570m ↗
26. Bisgaier C. L. · J. Lipid Res. · 1993 · 34 · 162510.1016/S0022-2275(20)36955-8 ↗
27. Semiramoth N. · ACS Nano · 2012 · 6 · 382010.1021/nn204928v ↗
28. Hillaireau H. · Biomaterials · 2013 · 34 · 483110.1016/j.biomaterials.2013.03.022 ↗
29. Chen Y. · Adv. Drug. Delivery Rev. · 2012 · 64 · 64010.1016/j.addr.2011.11.010 ↗
30. Lepeltier E. · Langmuir · 2013 · 29 · 1479510.1021/la403338y ↗
31. Lynch I. · Nano Today · 2008 · 3 · 4010.1016/S1748-0132(08)70014-8 ↗
32. Braeckmans K. · Nano Lett. · 2010 · 10 · 443510.1021/nl103264u ↗
33. Casals E. · ACS Nano · 2010 · 4 · 362310.1021/nn901372t ↗
34. Saha K. · Mater. Horiz. · 2014 · 1 · 10210.1039/C3MH00075C ↗
35. Schaffler M. · Biomaterials · 2014 · 35 · 345510.1016/j.biomaterials.2013.12.100 ↗
36. Kim H. R. · Biomacromolecules · 2007 · 8 · 79310.1021/bm060711a ↗
37. Fleischer C. C. · J. Phys. Chem. B · 2014 · 118 · 1401710.1021/jp502624n ↗
38. Abbott N. J. · Neurobiol. Dis. · 2010 · 37 · 1310.1016/j.nbd.2009.07.030 ↗
39. Gabathuler R. · Neurobiol. Dis. · 2010 · 37 · 4810.1016/j.nbd.2009.07.028 ↗
40. Sahay G. · J. Controlled Release · 2010 · 145 · 18210.1016/j.jconrel.2010.01.036 ↗
41. Rejman J. · Biochem. J. · 2004 · 377 · 15910.1042/bj20031253 ↗
42. Lakkaraju A. · J. Biol. Chem. · 2002 · 277 · 1508510.1074/jbc.M111764200 ↗
43. Kim H. R. · Cell. Mol. Life. Sci. · 2007 · 64 · 35610.1007/s00018-007-6390-x ↗
44. Wagner S. · PLoS One · 2012 · 7 · e3256810.1371/journal.pone.0032568 ↗
45. Dehouck B. · J. Cell. Biol. · 1997 · 138 · 87710.1083/jcb.138.4.877 ↗
46. Langdon R. G. · J. Biol. Chem. · 1953 · 200 · 13510.1016/S0021-9258(18)38446-1 ↗
47. Tenzer S. · Nat. Nanotechnol. · 2013 · 8 · 77210.1038/nnano.2013.181 ↗
48. Lepeltier E. · Langmuir · 2014 · 30 · 634810.1021/la5007132 ↗
49. Conner S. D. · Nature · 2003 · 422 · 3710.1038/nature01451 ↗
50. He B. · Biomaterials · 2013 · 34 · 430910.1016/j.biomaterials.2013.01.100 ↗
51. He L. · Cytometry A · 2003 · 53 · 3910.1002/cyto.a.10037 ↗
52. Gadella T. W. · J. Cell. Biol. · 1995 · 129 · 154310.1083/jcb.129.6.1543 ↗
53. Naik P. · J. Pharm. Sci. · 2012 · 101 · 133710.1002/jps.23022 ↗
54. Ragnaill M. N. · Eur. J. Pharm. Biopharm. · 2011 · 77 · 36010.1016/j.ejpb.2010.12.024 ↗
55. Ramoino P. · J. Microsc. · 2002 · 208 · 16710.1046/j.1365-2818.2002.01078.x ↗